Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Langenbeck's Archives of Surgery
Published in: Langenbeck's Archives of Surgery 3/2008

01-05-2008 | Case Management and Clinical Consequences

Uneventful splenectomy and cholecystectomy in a patient treated with anti-interleukin-6 receptor antibody therapy

Authors: Morihiko Ishizaki, Tetsuro Sasada, Akane Kunitomi, Yoshiteru Konaka, Masato Yagita, Shutaro Gunji, Michiyuki Kanai, Norihiro Nishimoto, Arimichi Takabayashi

Published in: Langenbeck's Archives of Surgery | Issue 3/2008

Login to get access

Abstract

Introduction

Interleukin-6 (IL-6) is a multifunctional cytokine that regulates various aspects of the immune responses, acute phase reactions, and hematopoiesis. In rodent models, IL-6 has been suggested to be one of the essential mediators for optimal acute phase responses to infection and tissue damage. However, in humans, the roles of IL-6 in acute phase responses after surgery remain poorly understood.

Case report

We present the first case report of successful splenectomy and cholecystectomy in a severe autoimmune-associated hemolytic anemia patient during treatment with a humanized anti-IL-6 receptor antibody.

Discussion

This unique case suggests that IL-6 is not an essential cytokine to safely perform surgical intervention and to prevent postoperative complications and that surgical intervention may not be contraindicated but can be selected as a therapeutic modality in patients treated with anti-IL-6 receptor antibody therapy.
Literature
1.
Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2:619–626PubMedCrossRef
2.
Nishimoto N, Yoshizaki K, Tagoh H, Monden M, Kishimoto S, Hirano T, Kishimoto T (1989) Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol 50:399–401PubMedCrossRef
3.
Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339–342PubMedCrossRef
4.
Gallucci RM, Simeonova PP, Matheson JM, Kommineni C, Guriel JL, Sugawara T, Luster MI (2000) Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J 14:2525–2531PubMedCrossRef
5.
Kunitomi A, Konaka Y, Yagita M, Nishimoto N, Kishimoto T, Takatsuki K (2004) Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia. Int J Hematol 80:246–249PubMedCrossRef
6.
Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627–2632PubMedCrossRef
7.
Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52:818–825PubMedCrossRef
8.
Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126:989–996PubMedCrossRef
9.
Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761–1769PubMedCrossRef
Metadata
Title
Uneventful splenectomy and cholecystectomy in a patient treated with anti-interleukin-6 receptor antibody therapy
Authors
Morihiko Ishizaki
Tetsuro Sasada
Akane Kunitomi
Yoshiteru Konaka
Masato Yagita
Shutaro Gunji
Michiyuki Kanai
Norihiro Nishimoto
Arimichi Takabayashi
Publication date
01-05-2008
Publisher
Springer-Verlag
Published in
Langenbeck's Archives of Surgery / Issue 3/2008
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-007-0217-y

Other articles of this Issue 3/2008

Langenbeck's Archives of Surgery 3/2008 Go to the issue

Original Article

Intraoperative biliary exploration through the left hepatic duct orifice during left hepatectomy in patients with left-sided hepatolithiasis

Mastery in Surgery

Professor Dr. Dr. h.c. Christian H. Herfarth, Heidelberg

Announcements

Announcements

Original Article

Synergistic effect of erythropoietin but not G-CSF in combination with curcumin on impaired liver regeneration in rats

How to do it

Living donor liver resection: A low-tech but highly efficient technique. The Regensburg experience

Original Article

Laparoscopic vs open resection of pancreatic endocrine neoplasms: single institution’s experience over 14 years